Selexipag for the treatment of pulmonary arterial hypertension.
Details
Serval ID
serval:BIB_A1BB2A3A6225
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Selexipag for the treatment of pulmonary arterial hypertension.
Journal
Expert review of respiratory medicine
ISSN
1747-6356 (Electronic)
ISSN-L
1747-6348
Publication state
Published
Issued date
05/2021
Peer-reviewed
Oui
Volume
15
Number
5
Pages
583-595
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
: Pulmonary arterial hypertension (PAH) is a rare pulmonary vasculopathy. This review focuses on selexipag, a prostacyclin receptor agonist validated for the treatment of PAH.
We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis.
Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.
We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis.
Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.
Keywords
Acetamides/therapeutic use, Administration, Oral, Antihypertensive Agents/therapeutic use, Humans, Pulmonary Arterial Hypertension/drug therapy, Pyrazines/therapeutic use, Endothelin receptor antagonist, guanylate cyclase stimulators, phosphodiesterase type 5 inhibitor, prostacyclin Pathway, pulmonary arterial hypertension, selexipag
Pubmed
Web of science
Create date
22/01/2021 11:39
Last modification date
09/01/2024 8:15
Usage data
